Renal Cell Carcinoma
Advertisement
PFS was improved with nivolumab plus cabozantinib.
The Two Onc Docs provide a brief overview of the the urothelial carcinoma, RCC, and prostate cancer presentations of note
Dr. Armstrong previews updates related to STAMPEDE, ARANOTE, LITESPARK-005, AMBASSADOR, and others.
A lack of research persists on the duration of therapy as well as the safety and efficacy of reinduction at progression.
The hypoxia-inducible factor 2α inhibitor, belzutifan, has shown clinical activity in patients with ccRCC.
In anticipation of ESMO, Dr. Katy Beckermann previews various clinical trials and studies to be presented in kidney cancer.
Patients either underwent 54 weeks of treatment with everolimus 10 mg per day or treatment with a matching placebo.
Dr. Braun shares insights on updates to the NCCN guidelines for RCC, highlighting how they could impact clinical practice.
AUC3 seeks to reshape the landscape of GU cancer management through interdisciplinary dialogue and consensus building.
Patients who received nivolumab plus ipilimumab experienced increased complete response rates compared with sunitinib.
Researchers stated that the novel data source has the potential to inform patient care.
Dr. Rini talks about the exciting sessions and entertainment in store for guests at The Uromigos Live and Unplugged 2024.
The panel concludes with an overview of advancements and upcoming trials in the treatment of nccRCC.
The panel weighs the progress and challenges of adjuvant pembro and addresses the toxicity profiles of IO/TKI regimens.
Researchers focused on the economic impact of disparities related to insurance coverage.
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
ACSS2 Inhibition as a Therapeutic Strategy in ccRCC: Impacts on HIF-2α, Metabolism, and Tumor Growth
The group discusses how blocking ACSS2 may affect immune cells in the tumor microenvironment. 
Drs. Beckermann, Rathmell, and Bacigalupa highlight the potential of ACSS2 as a therapeutic target in kidney cancer.
CEUS for the assessment of nccRCC can provide a more sensitive alternative to conventional ultrasound imaging.
The primary end point was ORR according to Immune Response Evaluation Criteria in Solid Tumors at 4 months.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.